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coronary artery disease in the Xinjiang Han
population for women in China
Zhenyan Fu†, Qing Zhu†, Yitong Ma*, Ding Huang, Shuo Pan, Xiang Xie, Fen Liu and Erdenbat ChaAbstract
Background: Cytochrome P450 (CYP) 2C9 is expressed in the vascular endothelium and metabolizes arachidonic
acid to biologically active epoxyeicosatrienoic acids (EETs), which have the crucial role in the modulation of
cardiovascular homeostasis. We sought to assess the association between the human CYP2C9 gene and coronary
artery disease (CAD) in Xinjiang Han Population of China.
Methods: 301 CAD patients and 220 control subjects were genotyped for 4 single-nucleotide polymorphisms
(SNPs) of the human CYP2C9 gene (rs4086116, rs2475376, rs1057910, and rs1934967) by a Real-Time PCR instrument.
The datas were assessed for 3 groups: total, men, and women via diplotype-based case–control study.
Results: For women, the distribution of genotypes, dominant model and alleles of SNP2 (rs2475376) showed
significant difference between the CAD patients and control participants (p = 0.033, P = 0.010 and p = 0.038,
respectively). The significant difference of the dominant model (CC vs CT + TT) was retained after adjustment for
covariates in women (OR: 2.427, 95% confidence interval [CI]: 1.305-4.510, p = 0.005). The haplotype (C-T-A-C) and
the diplotypes (CTAC/CTAC) in CYP2C9 gene were lower in CAD patients than in control subjects (p* = 0.0016,
and p* = 0.036 respectively). The haplotype (C-C-A-T) was higher in the CAD patients than in the control
subjects in women (p* = 0.016).
Conclusions: CC genotype of rs2475376 and C-C-A-T haplotype in CYP2C9 may be a risk genetic marker of CAD
in women. T allele of rs2475376, the haplotype (C-T-A-C) and the diplotype (CTAC/CTAC) could be protective
genetic markers of CAD for women in Han population of China.
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CAD is a complex multifactorial and polygenic disorder
thought to result from an interaction between an indi-
vidual's genetic makeup and different environments [1].
Increasing evidence from animals and clinical and epi-
demiological studies has repeatedly supported the likeli-
hood of a genetic contribution to CAD susceptibility
[2,3]. Cytochrome P450 (CYP) genes is a super family of
cysteine-heme enzymes, which catalyze the oxidation of
various drugs and endogenous substrates, such as vita-
min D, steroids, and fatty acids, including arachidonic* Correspondence: myt-xj@163.com
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unless otherwise stated.acid (AA) [4]. CYP enzymes of the P450 2C9 subfamily
are found in the liver, vascular smooth muscle, endothe-
lial cells of human aorta and coronary artery [5-7]. In
human liver, CYP2C9 is responsible for 50% of the epox-
ygenase activity, and metabolizes a wide variety of clinic-
ally important drugs, including losartan and S-warfarin [8,9].
In human heart, CYP2C9, as well as CYP2C8 and CYP2J2,
participates in metabolizing arachidonic acid to epoxyeicosa-
trienoic acids (EETs) [10,11]. EETs are supposed to play the
key role in endothelial cell homeostasis, showing pro-
tective vascular effects including vasodilatation, anti-
inflammtory, anti-apoptotic and anti-thrombotic effects
[12-14]. They are also involved in myocardial precondition-
ing and have cardioprotective effects by increasing postis-
chemic function and reducing myocardial infarct sizeThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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EETs, which determine susceptibility to the development of
CAD. In recent years, many studies have shown the poly-
morphisms of CYP2C9 gene (rs1057910) were associated
with the cardiovascular risk [17,18]. Given this background,
we sought to investigate the possible association between the
genetic variation of CYP2C9 and CAD in Xinjiang Han
population of China.
Methods
Ethical approval of the study protocol
This study was approved by the Ethics Committee of the
First Affiliated Hospital of Xinjiang Medical University
(Urumqi, China). It was conducted according to the
standards of the Declaration of Helsinki. Written in-
formed consent was obtained from all participants. All
participants explicitly provided permission for DNA ana-
lyses as well as collection of relevant clinical data.
Subjects
All patients and controls were enrolled from the First Af-
filiated Hospital of Xinjiang Medical University (Urumqi,
China) from January 2011 to April 2013. The study in-
volved 301 patients with CAD defined as the presence of
at least one significant coronary artery stenosis of more
than 50% luminal diameter on coronary angiography. 220
Control participants did not have coronary artery stenosis
and did not show clinical or electrocardio-graphic evi-
dence of myocardial infarction (MI) or CAD. Data and in-
formation about traditional coronary risk factors, including
hypertension, diabetes mellitus (DM), and smoking, were
collected from all study participants. The diagnosis of hyper-
tension was established if patients were on antihypertensive
medication or if the mean of 3 measurements of systolic
blood pressure (SBP) >140 mmHg or diastolic blood(kbp)0 2







Figure 1 Structure of the human CYP2C9 gene. This gene consists of
indicate introns and intergenic regions. Filled boxes indicate coding regionpressure (DBP) >90 mmHg, respectively. Diabetes mel-
litus was defined by fasting plasma glucose >7.0 mmol/L
and also if patients were taking antidiabetic medication or
insulin therapy. “Smoking” was classified as smokers (includ-
ing current or ex-smokers) or non-smokers. All patients
with impaired renal function, malignancy, connective tissue
disease, or chronic inflammatory disease were excluded.
Blood collection and DNA extraction
Blood samples were taken from all participants. The
blood samples were drawn into a 5 ml ethylene di-
amine tetraacetic acid (EDTA) tube and centrifuged at
4000 × g for 5 min to separate the plasma content.
Genomic DNA was extracted from the peripheral leu-
kocytes using standard phenol–chloroform method. The
DNA samples were stored at −80°C until use. When used,
the DNA was diluted to 50 ng/ul concentration.
Genotyping
There are 1375 SNPs for the human CYP2C9 gene listed in
the National Center for Biotechnology Information SNP
database (http://www.ncbi.nlm.nih.gov/SNP). Using the Hap-
loview 4.2 software and the HapMap phrase II database,
we obtained four tag SNPs (rs4086116, rs2475376,
rs1057910 and rs1934967) by using minor allele fre-
quency (MAF) > =0.01 and linkage disequilibrium pat-
terns with r2 > =0.5 as a cut off. We designated these
SNPs as SNP1, SNP2, SNP3, and SNP4 (rs4086116,
rs2475376, rs1057910 and rs1934967) in order of increasing
distance from the CYP2C9 gene 5′end (Figure 1). SNP1,
SNP2, and SNP4 are located in intron. SNP3(rs1057910) is
located in exon7, and had a non-synonymous substitution
amino acid change, which is defined by an A-to-C nu-
cleotide substitution that leads to an exchange of leu-









9exons separated by 8 introns. Boxes indicate exons, and lines
s. Arrows mark the locations of polymorphisms.
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Genotyping Assay (Applied Biosystems) using Taq amplifi-
cation, TaqMan® SNP Genotyping Assays were carried out.
The primers and probes used in the TaqMan® SNP Geno-
typing Assays (ABI) were chosen based on information at
the ABI website (http://myscience.appliedbiosystems.com).
Thermal cycling was done using the AppliedBiosystems
7900HT Fast Real-Time PCR System. Plates were read on
Sequence Detection Systems (SDS) automation controller
software v2.3 (ABI).PCR amplification was performed
using 3.0 μl of TaqMan Universal Master Mix, 0.15 μl
probes and 1.85 ddH2O in a 6-μl final reaction volume
containing 1 μl DNA. Thermal cycling conditions were
as follows: 95°C for 5 min; 40 cycles of 95°C for 15 s;
and 60°C for 1 min. All 96 wells Plates were read on
Sequence Detection Systems (SDS) automation con-
troller software v2.3 (ABI).
Biochemical analysis
Serum concentrations of total cholesterol (TC), triglycer-
ide (TG), glucose, high-density lipoprotein cholesterol
(HDL-C), low-density lipoprotein cholesterol (LDL-C),
blood ureanitrogen (BUN), creatinine (Cr) and uric acid
were measured using standard methods in the Central
Laboratory of the First Affiliated Hospital of Xinjiang
Medical University as described previously.
Statistical analysis
All continuous variables (e.g. age, BMI, cholesterol levels)








Number (n) 301 220 202
Age (years) 59.13 ± 8.97 57.64 ± 8.78 0.092 60.73 ± 9.12
BMI (kg/m2) 25.74 ± 3.39 25.44 ± 3.51 0.353 25.16 ± 5.16
Pulse (beats/min) 74.05 ± 10.13 74.13 ± 11.58 0.933 74.34 ± 10.8
BUN(mmol/L) 5.46 ± 1.58 5.53 ± 1.63 0.620 5.67 ± 2.12
Cr(umol/L) 75.07 ± 20.99 74.09 ± 22.71 0.625 77.50 ± 18.0
Glu (mmol/L) 6.10 ± 2.04 5.73 ± 1.91 0.043* 6.03 ± 1.99
TG (mmol/L) 1.75 ± 1.02 1.81 ± 1.23 0.545 1.71 ± 0.978
TC (mmol/L) 4.09 ± 1.08 4.24 ± 0.98 0.137 4.05 ± 1.70
HDL (mmol/L) 1.04 ± 0.37 1.15 ± 0.33 0.001* 1.10 ± 0.94
LDL (mmol/L) 2.44 ± 0.77 2..25 ± 0.80 0.004* 2.52 ± 2.20
EH (%) 63.6 51.54 0.072 61.4
DM (%) 19.95 10.15 0.029* 17.8
Smoke (%) 21.32 12.56 0.143 37.6
BMI, body mass index; BUN, blood urea nitrogen; Cr, creatinine; Glu, glucose; TG, tri
lipoprotein; EH, essential hypertension; DM, diabetes mellitus.
Continuous variable were expressed as mean ± standard deviation. P value of contin
variable was calculated by Fisher's exact test. *P>0.05.continuous variables conform to normal distribution, and
the study is a large sample data, so the differences of all
continuous variables between the CAD and the Control
groups were analyzed using T-test. The differences in the
frequencies of smoking, hypertension, DM, and CYP2C9
genotypes were analyzed using Fisher’s exact test. Chi-
square analysis was used to test the deviations of genotype
distribution from the Hardy-Weinberg equilibrium and to
determine the differences of allele or genotype frequencies
between patients and controls. Logistic regression analyses
were used to assess the contribution of the major risk fac-
tors. And adjusted estimations of conditioned relative risk
and 95 % confidence intervals (CIs) were done. All stat-
istical analyses were performed using SPSS 17.0 for
Windows (SPSS Institute, Chicago, USA). P-values were
considered to be significant at the 0.05 level. Haplotypes
were estimated using the expectation maximization algo-
rithm and the software SNPAlyze version 3.2 (Dynacom,
Yokohama, Japan), and using the SHEsis platform to verify
reliability [19,20]. The estimated diplotypes (combinations
of two haplotypes) in each subject were analyzed using
the software SNPAlyze version 3.2 (Dynacom, Yokohama,
Japan), The P value of haplotype and diplotype were re-
vised by False discovery rate.
Results
Table 1 showed the clinical characteristics of the CAD
patients (n = 301) and control participants (n = 220). For
total, men and women subjects, there was no significant









58.66 ± 8.43 0.077 62.53 ± 8.45 61.39 ± 7.81 0.364
25.46 ± 3.81 0.591 24.68 ± 6.32 25.58 ± 5.01 0.294
4 74.53 ± 11.04 0.874 73.46 ± 8.52 73.59 ± 12.30 0.937
5.55 ± 1.70 0.627 5.40 ± 1.83 5.36 ± 1.51 0.855
1 76.05 ± 10.00 0.790 74.54 ± 12.90 79.26 ± 10.66 0.762
5.65 ± 1.92 0.096 6.32 ± 2.53 5.84 ± 1.89 0.139
1.79 ± 1.35 0.498 1.94 ± 1.46 1.83 ± 1.01 0.306
4.14 ± 1.01 0.595 4.38 ± 1.07 4.38 ± 0.93 0.430
1.07 ± 0.289 0.737 1.08 ± 0.32 1.26 ± 0.34 0.368
2.29 ± 1.91 0.007* 2.36 ± 0.80 2.35 ± 0.88 0.461
48.7 0.032* 65.6 54.1 0.110*
8.9 0.043* 22.1 11.4 0.014*
23.0 0.008* 5.05 2.13 0.278
glyceride; TC, total cholesterol; HDL, high density lipoprotein; LDL, low density
uous variables was calculated by independent T-T test. The P value of categorical
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control study. We observed several differences between
the two groups of patients. As expected, several common
risk factors for CAD were significantly different between
the two subgroups: Glu, low HDL-C, high LDL-C, EH,
DM. For total, the serum concentrations of glucose (Glu),
LDL-C were significantly higher for CAD patients than
for control participants (p < 0.05), and the serum concen-
trations of HDL-C were significantly lower for CAD
patients than for control participants (p < 0.05). The
prevalence of DM was significantly higher for patients
with CAD than for control participants. For men, the
serum concentration of LDL-C was significantly higher
for CAD patients than for control participants (p < 0.05).
The prevalence of EH, DM, and smoking were signifi-
cantly higher for patients with CAD than for control par-
ticipants. For women, the prevalence of EH and DM were
significantly higher for patients with CAD than for control
participants.
Table 2 showed the distribution of genotypes and al-
leles of SNP1, SNP2, SNP3, and SNP4 of CYP2C9 gene.
The genotype distributions for each of the SNPs were in
agreement with the predicted Hardy-Weinberg equilib-
rium values (data not shown). For total, the distribution
of the four SNPs genotypes and alleles showed no differ-
ence between the CAD patients and control participants.
For men, the distribution of the dominant model of
SNP2 (rs2475376) (CC vs CT + TT) was higher in CAD
patients than in control participants (p = 0.045). For women,
the distribution of genotypes, of SNP2 (rs2475376) showed
significant difference between the CAD patients and control
participants (p = 0.033). The dominant model (CC vs CT+
TT) was significantly higher for CAD patients than for
control subjects (p = 0.010). The frequency of T allele
(rs2475376) was lower for CAD patients than for con-
trol subjects (p = 0.038).
Table 3 showed that multiple logistic regression ana-
lyses were done with or without EH, DM, and smoking.
The significant difference of the dominant model (CC vs
CT + TT) was retained after adjustment for covariates in
women, but not in men (for women, OR: 2.427, 95%
confidence interval [CI]: 1.305-4.510, p = 0.005; and for
men, OR: 1.372, 95% CI: 0.861-2.186, p = 0.184).
Table 4 showed patterns of linkage disequilibrium in
the CYP2C9 gene, with their |D′| and r2 values. |D′|
values from 0.7 to 1 indicate strong LD between a pair
of SNPs. |D′| values from 0.25 to 0.7 indicate moderate
LD and |D′| values of 0–0.25 indicate low LD. In our
study, two strong LD patterns were observed between
SNP1 and SNP2 (|D′| = 0.998), SNP2 and SNP3 (|D′| =
0.999). Three moderate LD patterns (|D′| values from
0.25 to 0.7) were observed between SNP1 and SNP3
(|D′| = 0.593), SNP1 and SNP4 (|D′| = 0.311), SNP2
and SNP4 (|D′| = 0.392). In addition, a low LD pattern(|D′| < 0.25) was observed between SNP3 and SNP4
(|D′| = 0.032) (Figure 2). Although LD pattern be-
tween SNP3 and SNP4 was low, there were linkage
disequilibrium between SNP3 and the two SNPs (SNP1,
SNP2), the same as SNP4. We can consider that all four
SNPs were located in one haplotype block. R2 values of
the four SNPs were all <0.5, it means the four SNPs can
not replace each other [21,22]. Then, we use the four
SNPs to establish haplotype by the order of SNP1-SNP2-
SNP3-SNP4 for all groups.
Table 5 showed the distribution of haplotypes in CAD
patient and control participants. There were twelve hap-
lotypes established in all subjects. The overall distribution
of the haplotypes were significantly different between the
CAD patients and the control subjects (all p < 0.0001).
The most frequence haplotype in this study was 0100
(C-T-A-C) haplotype. For women, the frequency of C-T-
A-C was significantly lower in the CAD patients than in
the control subjects (nominal p = 0.0032, adjusted p* =
0.016). In addition, the frequency of the 0001 (C-C-A-T)
haplotype was higher in the CAD patients than in the
control subjects in women (nominal p = 0.0016, adjusted
p* = 0.016). For total and men, the frequency of haplotypes
was no diffenerce between the CAD patients and the con-
trol subjects.
Table 6 showed the distribution of diplotypes in CAD
patients and control participants. For women, the two
diplotypes (CTAC/CTAC, CTAC/CCAC) in CYP2C9
gene were significantly lower in the CAD patients than
in the control subjects (nominal p = 0.004, and p = 0.016
respectively), while after revised by False discovery rate,
the diplotypes (CTAC/CCAC) was no difference be-
tween CAD patients than the control subjects (adjusted
p = 0.072).The homozygous diplotype (CTAC/CTAC)
was associated with decreased risk of CAD in women.
For total and men, the frequencies of diplotypes were no
diffenerce between the CAD patients and the control
subjects.
Discussion
Endogenous CYP metabolites such as epoxyeicosatrie-
noic acids (EETs), hydroxyeicosatetraenoic acids, prosta-
cyclin (PGI2), aldosterone, and sex hormones have been
demonstrated to be involved in coronary artery disease,
stroke, hypertension, and other cardiovascular diseases
[11]. Arachidonic acid can be metabolized by the CYP2C9
subfamily to EETs, which has been established to have five
physiological functions. First, EETs produces vasodilation
in a number of vascular beds by activating the smooth
muscle large conductance Ca2+-activated K+ channels
(BKCa) [6,14]. Second, EETs may act as endothelium-
derived hyperpolarizing factors (EDHF) [16], particularly
in the coronary circulation. EDHF possess potent vasodi-
lating effects hyperpolarize vascular smooth muscle cells
Table 2 Genotype and allele distributions in patients with CAD and control subjects
Total Men Women
CAD Control p CAD Control p CAD Control p
n = 301 n = 220 n = 202 n = 126 n = 99 n = 94
rs4086116 Genotype C/C 237 176 0.356 158 97 0.464 79 79 0.559
(SNP1) C/T 56 42 39 28 17 14
T/T 8 2 5 1 3 1
Dominant model CC 237 176 0.726 158 97 0.194 79 79 0.444
CT + TT 64 44 44 29 20 15
Recessive model TT 8 2 0.151 5 1 0.269 3 1 0.338
CT + CC 293 218 197 125 96 93
Allele C 530 394 0.449 355 222 0.932 175 172 0.312
T 72 46 49 30 23 16
rs2475376 Genotype C/C 104 76 0.834 60 51 0.122 44 25 0.033*
(SNP2) C/T 142 108 102 56 40 52
T/T 55 36 40 19 15 17
Dominant model CC 104 76 0.999 60 51 0.045* 44 25 0.010*
CT + TT 197 144 142 75 55 69
Recessive model TT 55 36 0.571 40 19 0.279 15 17 0.584
CT + CC 246 184 162 107 84 77
Allele C 350 260 0.758 222 158 0.051 128 102 0.038*
T 252 180 182 94 70 86
rs1057910 Genotype A/A 237 178 0.282 156 96 0.76 81 82 0.174
(SNP3) A/C 49 37 37 26 12 11
C/C 15 5 9 4 6 1
Dominant model AA 237 178 0.543 156 96 0.829 81 82 0.229
AC + CC 64 42 46 30 18 12
Recessive model CC 15 5 0.112 9 4 0.563 6 1 0.063
AC + AA 286 215 193 122 93 93
Allele A 523 393 0.233 349 218 0.965 174 175 0.082
C 79 47 55 34 24 13
rs1934967 Genotype C/C 209 152 0.126 144 79 0.203 65 73 0.161
(SNP4) C/T 55 61 49 42 6 19
T/T 11 7 9 5 2 2
Dominant model CC 209 152 0.933 144 79 0.105 65 73 0.065
CT + TT 92 68 58 47 34 21
Recessive model TT 11 7 0.77 9 5 0.832 2 2 0.958
CT + CC 290 213 193 121 97 92
Allele C 499 365 0.978 337 200 0.19 162 165 0.105
T 103 75 67 52 36 23
CAD, coronary artery disease.
The P value of genotype was calculated by Fisher's exact test.*P>0.05.
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inflammation responses by decreasing the cytokine-induced
endothelial expression of vascular cell adhesion molecule-1
(VCAM-1) and to decrease leukocytes adhesion to thevascular wall by inhibiting nuclear factor κB (NF-κB) and
IκB kinase [25]. Fourth, EETs have antithrombotic effects by
inhibiting platelet adhesion to endothelial cells, inhibiting
platelet aggregation, and enhancing the expression and
Table 3 Results of Logistic analysis for the dominant model (CC vs CT + TT) of SNP2
Total Men Women
OR 95% CI p OR 95% CI p OR 95% CI p
CC vs CT + TT 1.299 0.901-1.873 0.161 1.372 0.861-2.186 0.184 2.427 1.305-4.510 0.005*
EH 1.133 0.798-1.609 0.486 0.981 0.627-1.533 0.932 1.543 0.855-2.785 0.150
DM 1.149 0.671-1.968 0.614 1.095 0.574-2.089 0.783 1.186 0.425-3.313 0.745
Somke 1.307 0.917-1.862 0.139 0.952 0.592-1.530 0.839 2.905 0.536-15.741 0.216
EH, essential hypertension; DM, diabetes mellitus; CAD, coronary artery disease. * p>0.05.
Fu et al. Lipids in Health and Disease 2014, 13:143 Page 6 of 9
http://www.lipidworld.com/content/13/1/143activity of tissue plasminogen activator [26]. Fifth, in the kid-
ney, EETs are important regulators of glomerular filtration
by activating Na+/H+ exchanger and mediate pressure natri-
uresis and long-term control of blood pressure [27,28].
CYP2C9 polymorphisms might affect the biosynthesis and
activity of EETs, which determines susceptibility to the de-
velopment of CAD. In this study, we hypothesized that vari-
ability in CYP2C9 gene might affect the risk of CAD. We
genotyped four SNPs of the gene in a Han population, and
assessed the association between the CYP2C9 gene and
CAD using diplotype-based case–control analyses.
EH and DM were both common risk factors for CAD.
As expected, in our study, we found that the prevalence
of EH and DM were significantly higher for patients with
CAD than for control participants for women. The fre-
quency of T allele of SNP2 (rs2475376) was about 0.409,
which was slightly higher than the frequency of T allele
of the Chinese Han people (about 0.378) in PubMed
database. The distribution of genotypes, dominant model
and alleles of SNP2 (rs2475376) showed significant dif-
ference between the CAD patients and control partici-
pants (p = 0.033, P = 0.010 and p = 0.038, respectively).
However, the significant difference of the dominant
model (CC vs CT + TT) was retained after adjustment
for covariates in women, but not in men (for women,
OR: 2.427, 95% confidence interval [CI]: 1.305-4.510, p
=0.005; and for men, OR: 1.372, 95% CI: 0.861-2.186, p
=0.184). We speculated women carrying CC genotype
seem to have a lower ability to synthesize EETs. It
means CC genotype of rs2475376 may be an increased
risk factor of CAD. The frequency of T allelesTable 4 Pairwise linkage disequilibrium (| D'| above
diagonal and r2 below diagonal) for the four SNPs
| D'|
SNP SNP1 SNP2 SNP3 SNP4
r2 SNP1 0.998 0.593 0.311
SNP2 0.101 0.999 0.393
SNP3 0.255 0.127 0.032
SNP4 0.069 0.238 0.001
| D'|(rs2475376) was significantly lower for CAD patients
than for control subjects. Women carrying mutant T allele
seem to have a higher ability to synthesize EETs. It means
that T alleles (rs2475376) may be a decreased risk factor
of CAD.
For women, the frequency of the 0100 (C-T-A-C)
haplotype was significantly lower in the CAD patients
than in the control subjects, and the frequency of the
0001 (C-C-A-T) haplotype was higher in the CAD pa-
tients than in the control subjects. Human being is of
homologous chromosomes, therefore, diplotype is more
convincing than haplotype. For women, the homozygous
diplotype (CTAC/CTAC) was significantly lower in the
CAD patients than in the control subjects. It means that
C-T-A-C haplotype, the homozygous diplotype (CTAC/
CTAC) may be decreased risk factors of CAD. C-C-A-T
haplotype may be an increased risk factor of CAD.
These results of haplotype and diplotype were consistent
with the results of CC genotype and T allele of SNP2
(rs2475376).
In our study, we observed a protective effect of the
CYP2C9 mutant allele for the development of CAD only
in women. For the gender differences, we can explain it
by the following reasons. First, this could be attributed
to sex hormones. Sex hormones such as estrogens pro-
tect against oxidative stress and are known to be vasopro-
tective [17,18,29]. Second, there were some researches
[30,31], which show that estrogens protect the EETs
against being hydrolyzed by soluble epoxide hydrolase
(sEH). Hence, women carrying mutant T allele seem to
have a lower risk for suffering CAD. Third, this may be re-
lated to antioxidation of CYP2C9. CYP2C9 has been
shown to be a major source of reactive oxygen species
(ROS) within coronary artery endothelial cells [32]. Lower
formation of oxygen radicals in carriers of mutant alleles
might explain our findings.
In addition, many previous studies showed the poly-
morphisms of CYP2C9 gene (rs1057910) associated with
the cardiovascular risk. An increased risk of MI was
found in association with CYP2C9 variants (rs1057910)
among women [17,18,33,34]. In addition, there was the
study that showed men carriers of the CYP2C9 mutant
genotype (rs1057910) seem to have a lower risk for
Figure 2 Pairwise estimates of linkage disequilibrium (LD) between each CYP2C9 polymorphism is plotted for Han population using
SHEsis platform. Each polymorphism is numbered according to its position in the CYP2C9 gene as presented in Figure 1. (a) showed | D'| and
different colors represent different degree of linkage disequilibrium. The darker the color,wasthe stronger the degree of linkage disequilibrium
was (b) showed r2.
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which suggested CYP2C9 gene interaction with smoking
was associated with CAD [36]. In our study, it was not
found that rs1057910 of CYP2C9 gene was associated
with the risk of CAD. There might be ethnic and geo-
graphical environment factors explaining the difference














1 0100 CTAC 34.02 37.16 0.2699 0.6747 38.09 34
2 0000 CCAC 34.47 35.16 0.7979 0.9973 31.87 31.
3 1000 TCAC 2.5 2.48 0.9727 0.9727 1.55 3.0
4 1100 TTAC 1.22 ˉ 0.0221 0.2210 1.06 ˉ
5 0010 CCCC 5.4 4.3 0.4255 0.8510 5.83 6.0
6 1010 TCCC 2.27 2.34 0.9226 1.0000 2.28 2.8
7 0110 CTCC 3.9 1.52 0.0300 0.1500 3.75 1.2
8 0001 CCAT 10.05 9.18 0.5749 0.8212 8.16 13
9 1001 TCAT 2.49 3.12 0.5333 0.8888 3.88 2.
10 0101 CTAT 0 2.23 - - 0 1.3
11 1101 TTAT 2.25 0 - - 2.08 0
12 0011 CCCT 1.43 2.52 0.1746 1.47 3.2
13 1011 TCCT - - - - - -
The p value of haplotype was calculated by Fisher's exact test, and revised by False
‘0 represents major allele’ and 1 represents minor allele’.
“0100” refers respectively the major allele of the SNP1,minor allele of the SNP2,majo
The p value of each haplotype by the order of SNP1-SNP2-SNP3-SNP4 is relative toConclusion
In conclusion, CC genotype of rs2475376 and C-C-A-T
haplotype in CYP2C9 may be a risk genetic marker of
CAD in women. T allele of rs2475376, the haplotype (C-T-
A-C) and the diplotype (CTAC/CTAC) could be protective

















.7 0.2299 0.3831 26.02 41.38 0.0032* 0.016*
41 0.3916 0.3916 39 40.04 0.3360 0.4200
4 0.1537 0.3074 4.43 1.73 0.0761 0.1900
0.1472 0.3680 1.55 ˉ 0.0902 0.1503
8 0.3707 0.4119 4.41 1.41 0.0634 0.1133
9 0.3394 0.4243 2.34 2.02 0.3537 0.3537
5 0.1020 0.5100 4.06 1.18 0.0877 0.1754
.3 0.1000 1.0000 13.15 3.04 0.0016* 0.016*
7 0.2834 0.4049 0 3.72 - -
6 - - 1.74 3.18 0.1573 0.2242
- - 1.98 0 - -
7 0.1230 0.4100 1.31 1.05 0.3476 0.3862
- - 0 1.26 - -
discovery rate. * p>0.05;
r allele of the SNP3,major allele of the SNP4.
the other haplotypes as a group (overall p <0.0001).
Table 6 The distubution of diplotype of CYP2C9 in CAD patient and control participants
Total Men Women














CTAC/CTAC 47 52 1.511 0.893-2.557 0.122 1 40 28 0.824 0.421-1.611 0.334 0.334 7 24 0.251 0.105-0.876 0.004* 0.036*
2 1/2 0100/
0000
CTAC/CCAC 72 59 0.858 0.576-1.278 0.451 1 53 25 1.437 0.839-2.462 0.149 0.745 19 34 0.419 0.218-0.806 0.016* 0.072
3 2/2 0000/
0000
CCAC/CCAC 39 24 1.216 0.708-2.088 0.479 0.958 32 10 2.184 1.033-4.615 0.074 0.740 7 14 0.435 0.167-1.130 0.108 0.324
4 1/3 0100/
0001
CTAC/CCAT 19 18 0.756 0.387-1.477 0.412 1 12 13 0.549 0.242-1.245 0.195 0.488 7 5 1.354 0.414-4.425 0.351 0.526
5 1/4 0100/
0010
CTAC/CCCC 12 8 1.100 0.442-2.739 0.837 1 9 6 0.933 0.324-2.686 0.326 0.408 3 2 0.438 0.235-8.800 0.308 0.554
6 1/5 0100/
1001
CTAC/TCAT 10 5 1.478 0.498-4.386 0.479 1 9 3 1.912 0.508-7.201 0.220 0.440 1 2 0.469 0.042-5.264 0.424 0.424
7 2/5 0000/
1001
CCAC/TCAT 5 4 0.912 0.242-3.437 0.900 0.981 5 0 - - - 0 4 - - -
8 5/5 1001/
1001
TCAT/TCAT 3 1 2.205 0.228-21.338 0.484 0.830 1 1 0.622 0.039-10.032 0.294 0.49 2 0 - - -
9 1/7 0100/
1000
CTAC/TCAC 6 4 1.098 0.306-3.939 0.891 1 1 2 0.308 0.028-3.437 0.321 0.467 5 2 2.477 0.463-12.931 0.278 0.626
10 1/8 0100/
1010
CTAC/TCCC 3 3 0.728 0.146-3.642 0.698 1 1 1 0.622 0.039-10.032 0.327 0.363 2 2 0.948 0.131-6.874 0.383 0.431
11 2/8 0000/
1010
CCAC/TCCC 7 5 1.024 0.321-3.269 0.968 0.968 0 5 - - - 7 0 - - -
12 1/9 0100/
1011
CTAC/TCCT 5 8 0.448 0.144-1.387 0.153 0.918 4 6 0.404 0.112-1.461 0.154 0.513 1 2 0.469 0.042-5.264 0.353 0.454
The p value of diplotype was calculated by Fisher's exact test, and revised by False discovery rate.*p>0.05; The odds ratio (OR) and 95 % confidence interval (CI) of each diplotype are relative to the other diplotype as
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